Celcuity, Inc. (NASDAQ:CELC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $56.50.

CELC has been the subject of a number of analyst reports. Guggenheim initiated coverage on shares of Celcuity in a research report on Monday, September 22nd. They issued a “buy” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Celcuity in a report on Friday, October 3rd. Leerink Partners lifted their price objective on Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus assumed coverage on Celcuity in a research note on Tuesday, July 1st. They issued a “buy” rating and a $30.00 price target for the company.

Celcuity Stock Up 5.0%

CELC opened at $52.53 on Friday. Celcuity has a fifty-two week low of $7.57 and a fifty-two week high of $63.06. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The company has a market capitalization of $2.23 billion, a P/E ratio of -15.23 and a beta of 0.70. The stock has a fifty day moving average of $51.65 and a 200-day moving average of $27.13.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). On average, equities analysts expect that Celcuity will post -2.62 EPS for the current year.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares in the company, valued at approximately $5,497,500. The trade was a 44.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CELC. BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after buying an additional 3,766 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Celcuity during the 3rd quarter worth $79,000. AlphaQuest LLC raised its stake in Celcuity by 176.3% during the second quarter. AlphaQuest LLC now owns 7,087 shares of the company’s stock worth $95,000 after acquiring an additional 4,522 shares in the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in Celcuity during the first quarter worth about $115,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.